logo
Plus   Neg
Share
Email

Merck's Keytruda Fails Late Stage Clinical Trial

Merck & Co. (MRK) Monday said its cancer treatment Keytruda failed to meet goals in another late-stage study.

Merck said the Phase 3 Keynote-119 trial evaluating Keytruda, Merck's monotherapy for the second- or third-line treatment of patients with metastatic triple-negative breast cancer did not meet its primary endpoint of superior overall survival compared to chemotherapy.

"Metastatic triple-negative breast cancer is an aggressive and challenging disease to treat, especially after progression on initial standard-of-care treatment," said Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

"While we are disappointed by the outcome of this monotherapy trial, we are continuing to study KEYTRUDA in earlier stages of the disease and in combination with chemotherapy to address the unmet medical need of patients with triple negative breast cancer. We are grateful to the patients and investigators for their participation in this important study."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook has removed four separate networks of accounts, pages and groups for engaging in co-ordinated inauthentic behavior on Facebook and Instagram. These networks originated from Iran and Russia and primarily targeted the US, North Africa and Latin America. These networks often posted on both sides of political issues including topics like US elections, environmental issues, racial tensions. While reporting financial results for the third quarter on Tuesday, Lockheed Martin Corp. (LMT) raised its earnings and net sales guidance for the full-year 2019, and initiated net sales outlook for the full-year 2020. For fiscal 2019, the company now expects earnings of about $21.55 per share, up... Consumer goods giant Procter & Gamble on Tuesday reported a 12 percent increase in profit for the first quarter of fiscal 2020 from last year, driven by an increase in net sales and operating margin. Both revenue and core earnings per share for the quarter beat analysts' estimates. Looking ahead, the company raised its earnings and revenue growth guidance for the full-year 2020.
Follow RTT
>